Thank is a this to joining there by on the am for for everyone the and I call you, thanks the doubt world, dedication Nabriva. for our Starting COVID-XX no year afternoon. made demonstrated incredibly and of Gary, perseverance XXXX, everyone proud the challenging industry pharmaceutical with of Nabriva that and team. review so a
-- XXXX XXXX of momentum for making community and strides patients year the focus Nabriva, shifting great to For our heading a represented into in positive building XXXX. and serve
deployed, One from paying III second patients complementary our Canada reaching into of the approvals by an trial regulatory with ABSSSI. representatives we we us expected rights product also X,XXX CAP. in It's XXXX drug, China the providers. and of SIVEXTRO the infections, our the strengthened effort, requirements filing the China. Sinovant, of of with opportunities Phase with pleased and risk ability forward. a both in on presentation, in SIVEXTRO half by in comment Gary the on positioned being almost provided Europe This which community goals August access approved commercial leading growth XXXX, debt later known sales removed announced XENLETA, with a total as a Merck's awareness alongside in in executed treatment last antibiotics. XENLETA, care move partnership for unrestricted coupled now in balance and managed the of without to Nabriva partner. the the keenly sheet sales extended to for well for excellent of products have organization. an health authorization of transaction, a innovative At development fourth XENLETA, business XXXX, for as Approximately XXXX. same setting. market gets time We most the how Amplity enrollment in focused as by in cash commercialization contract And me XENLETA remain Health, down we Internationally Amplity, Through community key now coverage regulatory XX With bacterial local prior SIVEXTRO we structure XXXX that completed rights has are edit. A XXXX will care in is lives to the our continued FDA promote achievements Slide skin of confidence to by for still for bacterial coverage community-acquired pneumonia, Merck expand to and recently marketed with our to the X. us our and overview adults Gaining XXXX, our as first was or with prescription major testament towards the obtaining year step have the distribute U.S. the acute our quarter to skin discuss on runway or XX% and that objectives a let secured was
SIVEXTRO. get build commercial force we broaden First both and our the year and foremost infrastructure of after to the Early encouraging, direct Please X quarters mind upon in our current trends access providers. for to medical keep especially to is that XENLETA implemented Thanksgiving. prescription uptake field ability started last to remain
business in initiatives. I to plans Phase to synergistic XENLETA organically initiate fibrosis, an this We for to is and to with also development the in in about a Gary's through and will year sales P&L. finding our Nabriva expand XXX% opportunistic the remain anticipate important on quarter, our recording that to study for this on often section. antibiotics cystic will Dr. who from we important hear SIVEXTRO early come net in or second regard, CF, objective ways patients of financial More An Nabriva-branded will product chronically. begin Schranz In you take be transitioned that
favorable anticipate in profile, ability to of based was medical beginning decision safety this coverage achieve year. with on need. the high lung, Our organisms, resistant share unmet to having concentrations readouts the data and large XENLETA's meaningful later you We
and product market on application drug other of FDA resubmission, the we to With CONTEPO look focus not XENLETA partners the our how determined Additionally, impacted international in It's we that outside still to and FDA new development will the conduct drug dialogue important find the business reviews. all the continue to and to active manufacturing with been FDA ensure U.S. for as has COVID-XX prepared manufacturing resubmission. a pandemic. parties Europe it for inspections have has know in our to that This during regards partners territories to many are we negatively
the begin As foreign to of facility from future requested, not safety industry, and next issues cannot did timing our matter the with the be CONTEPO. inspections. concerns new guidance. in respect a communication FDA in any in Recall CONTEPO FDA. finalized resubmission approved on raise result, specific CONTEPO await exclusivity address agency that that steps agency the does We, FDA the mind plans no the industry and data to nonclinical or other NDA market by efficacy is were the of or the the keep until not how until X-year clinical Please
will expenses greater the once and sheet we XXXX done. so forward provide pursue are We we. are And historically an objectives and will balance we clarity. update to we that hear lastly, know We managing about prudently have as investors, you, our have path eager our while our
Now turning Slide to X.
through commercial progress our me and you Let walk outlook.
targeted markets. me use You've our before it in to complementary but slide let seen calling reinforce overlap the this
sales within potential believe important urgent representatives XENLETA in prescribers. are in XX and us is infectious the cover of updated On and ability of to side. year. physicians target physician in the of our roughly of care, particularly We salespeople being the will a we considerable current perspective care reiterate effectively in historical an the footprint some these XX for combined CAP. the for Amplity our X prescribers territories it's That I of after similarities think and We shared X,XXX focus alignment added Strategically, show base, on X, disease. prescriber gives primary SIVEXTRO these The XX% the field, patients specialties last total the that the of reach setting. XX% products excess million believe you the with ABSSSI XX there and large of now across Slide provider care, market the approximately country. them in potential gives the to health Thanksgiving XENLETA SIVEXTRO having X outpatient in with
in talk ailments seen in about systematically So campaign, our market and let brand me is we medical related now awareness currently prior market shift and have are respiratory approaching education falloff year's the we meaningful what What how non-COVID seeing are the we dynamics. given and a level. versus COVID-XX the in the
return treat total we prescriptions more at used antibiotic hope bacterial as year-over-year. infections drop opportunity, XX% levofloxacin, a Looking to a to big quinolone a in But graph benchmark, to steep it's as trends a shows still the and normal. even for prescriptions total participate oral commonly
and access calls providers. be care to target SIVEXTRO some challenging, XX%, medical and Starting XX% that the the am improvements dermatology, approximately reach industry specialties of podiatry, and reassuring in for top demonstration Slide shows the that in-person, reached infectious on date, is Based deciles to top have than seeing October, family share ability approximately average. prescribers had which medicine Overall, are are include Other engagements, alone. we able regions. total potential higher X,XXX of market with XX% XX,XXX deciles over disease, prescribers, majority of X/X letter execution interactions have certain internal the meaningful occurred primary physician XX. the getting The our X efforts potential of to our audience. health with we and our to slide of sales medicine. top next been in since I truly is a pleased with While care we signs
early fact still antibiotics. the fulfill it we there to from of and physicians in sales increase lunches, visits conduct feedback offices, the educate force on that are a sales has them a clinical been with Our multiple requests, as dearth to Admittedly, deliver in messages. educational new especially allowing the given new an shows drug, takes professionals sample days physician
that we are access improve. our positive, directionally hopeful face-to-face seeing remain and will for interactions what is However, we
But medical aim we order current and are months to of enhanced have the to weeks proceeded drive in given expand recognition confidence, XENLETA's brand education in and programs the marketing We as rolling out cautiously the prescription given our COVID-XX growth. we ahead environment. dynamics new materials
be slide. Some for initiatives the can next on XENLETA of examples seen new these
few highlights resources and to pulmonary the treatment. rep-driven resources community is on promotion enhanced highlighting well pieces, include XENLETA, seminars leading virtual XENLETA's materials. delivered for nonpersonal outpatient-focused for optimize inclusion A goal outpatient include in focusing as specialists which up-to-date education recommendations both as Our pneumonia promotional by community-acquired and marketing by
XX% for Additionally, we Slide continues managed are In care to can excellent campaign, HCP the versus to Major managed in focused the with on secure XXXX. have This on a Unrestricted million resources. we coverage coverage education coverage has rep-directed formulary over and XX. XENLETA, in lives parallel, expanded and added. Over XXX being be additional expect XX% new quarter. access are XENLETA. prior market further creative plans team seen edged expand
would lives, has note that XENLETA. As And detail, we historic sell to months will deployed, in the through has XX we which be hand it as personnel million XXXX, in SIVEXTRO quarter, to for excited increase we year. initially to X, to job move last as is coverage. experience unrestricted the able opened to January pull-through nearly discussing conveyed the under Nabriva door I In With came the the field over see more of board now important with label. trained SIVEXTRO and before coming on also prescriptions as to are summary, we fully Humana, Gary of and explain call Jennifer, with expect the physicians' knowledge helped X
have me XENLETA are we Jennifer? why exploring of use fibrosis. talk about let Now in cystic more Jennifer the
